2 Top Healthcare Stocks to Buy Right Now
Biotech investors are always looking for ways to reduce risk. One method is to focus on stocks with drugs that have come out of phase 3 trials with good news. With enough research, you can usually figure out the odds of approval from the Food and Drug Administration (FDA), and how large the market opportunity is. That's often a good time to buy an unprofitable biotech.
Aurinia Pharmaceuticals (NASDAQ: AUPH) is filing a new drug application for its lupus drug, voclosporin, later this year. And Immunomedics (NASDAQ: IMMU) is waiting for the FDA to approve its drug for triple-negative breast cancer, sacituzumab govitecan. Both of these stocks appear undervalued, given the high likelihood of drug approval from the FDA and the market opportunity that lies ahead.
Image source: Getty Images.
Source Fool.com
